Big news in the world of molecular diagnostics:
As of July 13, 2025, PGX testing will be officially covered under the National Government Services (NGS) Medicare Administrative Contractor (MAC) region through a new Local Coverage Determination (LCD).

This update is a major step forward for labs offering pharmacogenomic (PGX) testing. But with opportunity comes complexity—and navigating Medicare’s coverage criteria, documentation expectations, and coding standards will be critical for maximizing reimbursement.

What Is the New LCD?

The new LCD (linked here) provides guidance on the medical necessity of PGX testing, coverage conditions, and clinical scenarios where testing is considered reimbursable. This decision by NGS signals a growing recognition of the value of pharmacogenomics in personalized medicine and patient care optimization.

Why This Matters

For physician-owned labs, hospital systems, and molecular diagnostic providers, this policy change unlocks new revenue streams—but also introduces new layers of compliance:

• Proper documentation to support medical necessity

• Accurate coding aligned with the LCD

• Awareness of denied claims trends across payors

• Ability to interpret LCDs and coverage policies across MAC regions

Missing any of these elements could lead to underpayment—or worse, recoupments and audits.

How Lab Revenue Navigator Can Help

At Lab Revenue Navigator, we don’t just do billing—we bridge the gap between clinical potential and financial performance.

With deep expertise in:

• MAC policy navigation

• PGX reimbursement strategy

• Coding and compliance audits

• Data-driven trend analysis

—we help your lab not only stay compliant but maximize every dollar you’re entitled to.

Ready to Capture the Opportunity?

If your lab offers PGX testing and is in an NGS jurisdiction, the time to act is now. We’re helping clients analyze policy, structure clinical documentation, and prepare for this July rollout.

Contact us today to schedule a free consult on how this LCD could impact your revenue.